- $315.99m
- $1.24bn
- $0.89m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 386.29 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -78.31% | ||
| Return on Equity | n/a | ||
| Operating Margin | -21664.55% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | 0.08 | 0.89 | 0.7 | 0.41 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Prokidney Corp. is a late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD). The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.
Directors
- James Coulston CFO (50)
- Darin Weber SVP (57)
- Todd Girolamo OTH (61)
- Pablo Legorreta NEC (62)
- William Doyle LED (63)
- Alan Lotvin IND (64)
- Jose Ignacio Jimenez Santos IND (51)
- Jennifer Fox IND (54)
- Bruce Culleton CEO (58)
- Gregory Madison OTH (57)
- Kenneth Locke CTO
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- July 1st, 2025
- Public Since
- June 30th, 2021
- No. of Shareholders
- 33
- No. of Employees
- 231
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 302,381,712
- Address
- 2000 Frontis Plaza Blvd., Suite 250, WINSTON-SALEM, 27103
- Web
- https://prokidney.com
- Phone
- +1 3369997028
- Auditors
- Ernst & Young LLP
Latest News for PROK
Upcoming Events for PROK
Q4 2026 Prokidney Corp Earnings Release
Similar to PROK
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
Acurx Pharmaceuticals
NASDAQ Capital Market
FAQ
As of Today at 12:47 UTC, shares in Prokidney are trading at $1.05. This share price information is delayed by 15 minutes.
Shares in Prokidney last closed at $1.05 and the price had moved by -54.17% over the past 365 days. In terms of relative price strength the Prokidney share price has underperformed the S&P500 Index by -59.18% over the past year.
The overall consensus recommendation for Prokidney is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreProkidney does not currently pay a dividend.
Prokidney does not currently pay a dividend.
Prokidney does not currently pay a dividend.
To buy shares in Prokidney you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.05, shares in Prokidney had a market capitalisation of $315.99m.
Here are the trading details for Prokidney:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: PROK
Based on an overall assessment of its quality, value and momentum Prokidney is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Prokidney is $6.50. That is 522.01% above the last closing price of $1.05.
Analysts covering Prokidney currently have a consensus Earnings Per Share (EPS) forecast of -$0.57 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Prokidney. Over the past six months, its share price has underperformed the S&P500 Index by -38.37%.
As of the last closing price of $1.05, shares in Prokidney were trading -40.79% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Prokidney PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.05.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Prokidney's management team is headed by:
- James Coulston - CFO
- Darin Weber - SVP
- Todd Girolamo - OTH
- Pablo Legorreta - NEC
- William Doyle - LED
- Alan Lotvin - IND
- Jose Ignacio Jimenez Santos - IND
- Jennifer Fox - IND
- Bruce Culleton - CEO
- Gregory Madison - OTH
- Kenneth Locke - CTO